bioAffinity Technologies
BIAFW
3 hedge funds and large institutions have $47.1K invested in bioAffinity Technologies in 2025 Q3 according to their latest regulatory filings, with funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 1 closing their positions.
7% more capital invested
Capital invested by funds: $44.2K → $47.1K (+$2.92K)
12.9% less ownership
Funds ownership: 21.24% → 8.34% (-13%)
25% less funds holding
Funds holding: 4 → 3 (-1)
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CS
Clear Street
New York
|
+$28 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$26.5K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$252 |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$128 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CS
1
Clear Street
New York
| $18.3K | +$28 | +198 | +0.4% |
|
|
2
UBS Group
Zurich,
Switzerland
| $15.7K | -$128 | -903 | -2% |
|
|
3
Citadel Advisors
Miami,
Florida
| $13.2K | -$252 | -1,771 | -5% |
|
|
AC
4
Armistice Capital
New York
| – | -$26.5K | -204,082 | Closed |
|
BIAFW Hedge Fund Activity: Q3 2025 in Review
3 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in bioAffinity Technologies (BIAFW) for Q3 2025, worth a combined $47.1K — up 6.6% from $44.2K a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of BIAFW and 0 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 1 added.
The largest buyer was Clear Street, adding an estimated $28. The largest seller was Armistice Capital, exiting entirely with an estimated $26.5K sold.
- 3 institutional investors held bioAffinity Technologies (BIAFW) as of Q3 2025, down from 4 in Q2 2025.
- Funds reported $47.1K of bioAffinity Technologies stock for Q3 2025, up 6.6% quarter-over-quarter.
- 0 funds opened new bioAffinity Technologies positions in Q3 2025 and 1 closed out, a net change of -1 holder.
- The largest bioAffinity Technologies buyer in Q3 2025 was Clear Street, an estimated $28 added.
- The largest bioAffinity Technologies seller in Q3 2025 was Armistice Capital, an estimated $26.5K sold.
Based on aggregated 13F filings for Q3 2025.